SCHEMBL1641877

SCHEMBL1641877

O=C(O)CNC(=O)c1c(O)c(C(=O)NCc2ccncc2)c(O)n(Cc2ccccc2Br)c1=O

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN3 Q9H6Z9 5/20 0.70
LMNA P02545 4/20 0.50
USP2 O75604 3/20 0.50
TSHR P16473 3/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
MAPT P10636 2/20 0.50
EGLN1 Q9GZT9 4/20 0.49
KDM4E B2RXH2 3/20 0.48
ALDH1A1 P00352 3/20 0.48
HPGD P15428 2/20 0.48
TDP1 Q9NUW8 1/20 0.48
ALOX12 P18054 2/20 0.48
POLB P06746 2/20 0.48
PKM P14618 1/20 0.48
ALOX15 P16050 1/20 0.48
HTT P42858 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
KMT2A Q03164 2/20 0.47
HIF1A Q16665 1/20 0.42
MEN1 O00255 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1640587 0.89 EGLN3 (0.73) EGLN3LMNAUSP2TSHRSMN1; SMN2
SCHEMBL1642144 0.86 EGLN3 (0.66) EGLN3LMNAUSP2TSHRSMN1; SMN2
SCHEMBL1641678 0.86 EGLN3 (0.66) EGLN3LMNAUSP2TSHRSMN1; SMN2
SCHEMBL1640610 0.83 EGLN3 (1.00) EGLN3EGLN1KDM4EALDH1A1TDP1
SCHEMBL1642420 0.83 EGLN3 (0.53) EGLN3LMNATSHRSMN1; SMN2EGLN1
SCHEMBL1642454 0.82 EGLN3 (0.59) EGLN3EGLN1HPGDHIF1A
SCHEMBL1641965 0.81 EGLN3 (0.58) EGLN3LMNASMN1; SMN2EGLN1KDM4E
SCHEMBL12727580 0.79 EGLN3 (0.56) EGLN3EGLN1KDM4EALDH1A1HTT
SCHEMBL1642591 0.79 EGLN3 (0.56) EGLN3EGLN1HIF1A
SCHEMBL1642035 0.79 EGLN3 (0.69) EGLN3LMNAEGLN1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
WO-2009158315-A1 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS HIF1AN, EGLN2, EGLN3 EGLN3 3/4885LMNA 3462/4885USP2 1716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.